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Abstract
Background: Earlier detection of second breast cancers after primary breast cancer (PBC) treatment improves survival, 
yet mammography is less accurate in women with prior breast cancer. The purpose of this study was to examine women 
presenting clinically with second breast cancers after negative surveillance mammography (interval cancers), and to 
estimate the five-year risk of interval-invasive second cancers for women with varying risk profiles.
Methods: We evaluated a prospective cohort of 15 114 women with 47 717 surveillance mammograms diagnosed with stage 
0-II unilateral PBC from 1996 through 2008 at facilities in the Breast Cancer Surveillance Consortium. We used discrete 
time survival models to estimate the association between odds of an interval-invasive second breast cancer and candidate 
predictors, including demographic, PBC, and imaging characteristics. All statistical tests were two-sided.
Results: The cumulative incidence of second breast cancers after five years was 54.4 per 1000 women, with 325 surveillance-
detected and 138 interval-invasive second breast cancers. The five-year risk of interval-invasive second cancer for women 
with referent category characteristics was 0.60%. For women with the most and least favorable profiles, the five-year risk 
ranged from 0.07% to 6.11%. Multivariable modeling identified grade II PBC (odds ratio [OR] = 1.95, 95% confidence interval 
[CI] = 1.15 to 3.31), treatment with lumpectomy without radiation (OR = 3.27, 95% CI = 1.91 to 5.62), interval PBC presentation 
(OR = 2.01, 95% CI 1.28 to 3.16), and heterogeneously dense breasts on mammography (OR = 1.54, 95% CI = 1.01 to 2.36) as 
independent predictors of interval-invasive second breast cancers.
Conclusions: PBC diagnosis and treatment characteristics contribute to variation in subsequent-interval second breast 
cancer risk. Consideration of these factors may be useful in developing tailored post-treatment imaging surveillance plans.
Advances in screening and treatment of primary breast cancer 
have improved survival for many women, and the number of 
breast cancer survivors will continue to increase (1–3). Women 
surviving their initial breast cancer diagnosis remain at risk 
of subsequent local/regional recurrence in the index breast or 
new primary cancers in the contralateral breast (“second breast 
cancers”), which are associated with increased rates of distant 
metastases and breast cancer mortality (4,5).
Post-treatment imaging surveillance is an essential element in 
survivorship care, as the earlier detection of second breast cancers 
permits interventions to improve survival and maintain quality 
of life (6,7). Surveillance mammography after breast cancer treat-
ment is associated with decreased breast cancer mortality (8–11). 
Current surveillance recommendations are for physical examina-
tion and annual mammography (12–14), as studies to date have 
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Yet screening mammography has lower sensitivity in women 
with a personal history of breast cancer, particularly within the 
first five years of primary breast cancer (PBC) diagnosis (18), pos-
sibly because of patient, tumor, and treatment factors (19), or 
other as yet unidentified factors. Approximately 35% of second 
breast cancers present as interval cancers following a negative 
screening mammogram (10,18,20). Recent evidence also sug-
gests that interval cancers presenting after negative mammo-
graphic screening may be more biologically aggressive (21).
Supplemental surveillance as an adjunct to mammography 
may lead to earlier detection and treatment of second cancers, 
if applied in appropriate groups of women. In this study, we esti-
mated interval-invasive second breast cancer risk during the 
first five years of post-treatment surveillance. In addition, we 
sought to identify characteristics of women most likely to pre-
sent with interval-invasive second breast cancers based on fac-
tors known at the time of PBC diagnosis and treatment—patient 
demographic, tumor, and imaging characteristics.
Methods
Study Setting and Data Sources
We included surveillance mammograms for women with prior 
breast cancer performed from 1996 through 2008 at facilities in 
five Breast Cancer Surveillance Consortium (BCSC) registries (22): 
Carolina Mammography Registry (North Carolina), Group Health 
Registry (Washington State), New Hampshire Mammography 
Network, New Mexico Mammography Project, and Vermont 
Breast Cancer Surveillance System. Registries collected data 
from community radiology facilities including patient charac-
teristics and clinical information. Radiologists’ assessments, 
recommendations, and mammographic breast density used the 
American College of Radiology’s Breast Imaging Reporting and 
Data System (BI-RADS) (23). Breast cancer diagnoses and tumor 
characteristics were obtained by linking BCSC data to pathology 
databases, regional Surveillance, Epidemiology, and End Results 
(SEER) programs, and state tumor registries. Data were pooled at 
a Statistical Coordinating Center (SCC). Registries and the SCC 
received institutional review board approval for data collection 
and analysis. All procedures were Health Insurance Portability 
and Accountability Act–compliant, and registries and the SCC 
received a Federal Certificate of Confidentiality for the identities 
of women, physicians, and facilities.
Participants
We included all women with incident ductal carcinoma in situ 
(DCIS) or stage I-II invasive carcinoma diagnoses, except those 
treated with bilateral mastectomy. We identified women who 
received mammography at BCSC facilities within two years 
before primary breast cancer diagnosis or one year afterward. 
We defined a surveillance mammogram as one indicated as a 
routine examination by the radiologist or technologist, exclud-
ing examinations within nine months of a prior mammogram or 
where the woman reported symptoms (18–20). For each woman 
we included all surveillance mammograms after PBC diagno-
sis until the first of diagnosis of second breast cancer, death, or 
disenrollment from the health care system (for women in the 
Group Health registry) and included no subsequent mammo-
grams after the first of these events. Because some women may 
have received mammograms outside of the BCSC, women were 
also censored at the time of a discrepancy six months or more 
between observed and self-reported time of prior mammogra-
phy in the BCSC database.
Measures and Definitions
Demographic characteristics, history of first-degree relatives 
with breast cancer, and menopausal status were obtained on 
a self-administered questionnaire (22) completed by women 
at each mammography visit. Breast density was categorized 
by radiologists using BI-RADS breast density categories (23): 
1  =  almost entirely fat, 2  =  scattered fibroglandular densities, 
3 = heterogeneously dense, 4 = extremely dense.
PBCs were classified by stage, grade, hormone receptor status, 
receipt of adjuvant systemic therapy (chemotherapy or hormo-
nal therapy), and primary surgery (breast conservation, mas-
tectomy) based on records from cancer registry and pathology 
databases that included treatments received within six months 
of initial diagnosis. Stage was defined using the American Joint 
Committee on Cancer (AJCC) staging system, 6th edition (24). 
Time since PBC was the difference between PBC diagnosis date 
and surveillance mammogram date. For missing cancer registry 
surgery information, self-reported mastectomy and lumpec-
tomy history (collected within 18  months after diagnosis and 
before second breast cancer diagnosis) was used.
PBC mode of detection was defined using previously 
established definitions (25): screen-detected (closest screen-
ing mammogram within two years prior to diagnosis is posi-
tive), interval cancer (closest screening mammogram prior 
to diagnosis is negative), clinical/diagnostic detection (only 
diagnostic mammograms prior to cancer diagnosis), or other 
(screening mammogram with missing results or with follow-
up recommended but no subsequent mammogram). In clas-
sifying mode of detection, including mammograms up to two 
years before PBC diagnosis enabled accounting for women 
screened at either one- or two-year intervals. Women with 
no screening or diagnostic mammograms in two years before 
PBC diagnosis or 30 days afterward were considered to have 
missing mode of detection data. In sensitivity analyses, we 
redefined mode of detection using a one year look-back 
period (26).
Second breast cancer outcomes were defined as DCIS or 
invasive breast cancer in either the index or contralateral breast, 
identified within 12 months of a surveillance mammogram and 
prior to the next surveillance mammogram by either tumor 
registry or institutional pathology data. Second breast cancer 
outcomes were further defined as surveillance-detected if the 
initial surveillance mammogram was positive (radiologist’s 
BI-RADS (23) assessment of 0, 4, 5, or 3 with recommendation for 
immediate evaluation). An interval-invasive second cancer was 
defined when an invasive second cancer was observed after an 
initial surveillance mammogram with negative results (radiolo-
gist’s BI-RADS assessment of 1, 2, or 3 without recommendation 
for immediate follow-up).
Statistical Analysis
Treating the surveillance mammography examination as the 
unit of analysis, we evaluated the distribution of surveillance 
mammograms, second breast cancers, and interval-invasive 
second cancers by demographic, imaging and surveillance 
characteristics, and characteristics of the first cancer and its 
treatment. We summarized follow-up available for women 
with and without second cancer diagnoses using lasagna plots 
(27,28), allowing for longitudinal trend examination (29). We 
compared observed incidence rates across surveillance rounds 
using a chi-square test (two-sided). We estimated the overall 
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surveillance-detected and interval-invasive second cancers 
using discrete-time survival models.
We also used discrete-time survival models to estimate 
the five-year cumulative probability of an interval-invasive 
cancer following PBC treatment (30,31). We parameterized our 
model by assuming a logistic relationship between the prob-
ability of an interval-invasive breast cancer at each surveil-
lance mammography round and covariates of interest. We first 
fit a “minimally adjusted model” separately for each covari-
ate of interest, adjusting for BCSC registry and surveillance 
round. We then fit a “fully adjusted” model that included all 
covariates simultaneously. Estimates of the probability of an 
interval-invasive second cancer at each screening round were 
aggregated across rounds to give a woman-level estimate of 
the five-year cumulative probability of an interval-invasive 
cancer.
To better understand the range of risk for an interval-inva-
sive second breast cancer for women with varying combinations 
of risk factors, the fully adjusted model was also used to gener-
ate risk estimates for three profiles. The first “referent” profile 
used referent categories for all predictors. Women in this profile 
were non-Hispanic white, post-menopausal, age 60 to 69 years, 
with no family history of breast cancer, who were diagnosed 
with stage I, grade I, hormone receptor–positive first cancers, 
treated with mastectomy and who received no adjuvant ther-
apy. The most favorable and least favorable risk profiles were 
created after the fully adjusted model was developed. The most 
favorable profile used referent categories for non-statistically 
Figure 1. Number of mammograms available and length of follow-up stratified by outcome. Colors shading from light gray to dark gray indicate total number of screen-
ing mammograms at or prior to the current year. White indicates no mammography in that year. Black indicates censored from observation because of death, cancer 
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Table 1. Distribution of variables in women with a personal history of breast cancer who underwent surveillance mammography, 1996–2008*
Variable (proportion  
missing data for variable where applicable)




No. invasive interval 
second cancers (%)
Total 47 717 (100) 325 138
Demographic characteristics
Age at mammography, y
<40 596 (1.2) 3 (0.9) 7 (5.1)
40–49 5283 (11.1) 42 (12.9) 25 (18.1)
50–59 12 621 (26.4) 84 (25.8) 41 (29.7)
60–69 12 120 (25.4) 83 (25.5) 19 (13.8)
70–79 11 564 (24.2) 75 (23.1) 36 (26.1)
80+ 5533 (11.6) 38 (11.7) 10 (7.2)
Race/ethnicity (3.6%)
White, non-Hispanic 39 423 (85.7) 277 (88.8) 110 (84.6)
Black, non-Hispanic 1582 (3.4) 8 (2.6) 4 (3.1)
Hispanic 3262 (7.1) 17 (5.4) 11 (8.5)
Asian, Pacific Islander 737 (1.6) 5 (1.6) 3 (2.3)
Other 1000 (2.2) 5 (1.6) 2 (1.5)
Menopausal status (13.2%)
Post 37 614 (90.9) 248 (86.7) 93 (82.3)
Peri- 740 (1.8) 7 (2.4) 4 (3.5)
Pre- 3042 (7.3) 31 (10.8) 16 (14.2)
First-degree family history of breast cancer (15.4%)
No 30 883 (76.5) 191 (69.2) 85 (71.4)
Yes 9507 (23.5) 85 (30.8) 34 (28.6)
First cancer diagnosis and treatment characteristics
Age at first breast cancer, y (0%)
<40 1579 (3.3) 12 (3.7) 15 (10.9)
40–49 9448 (19.8) 71 (21.8) 36 (26.1)
50–59 13 116 (27.5) 87 (26.8) 31 (22.5)
60–69 11 783 (24.7) 84 (25.8) 29 (21)
70–79 9274 (19.4) 58 (17.8) 20 (14.5)
80+ 2517 (5.3) 13 (4) 7 (5.1)
Stage of first breast cancer (0%)
0 9431 (19.8) 111 (34.2) 31 (22.5)
I 23 349 (48.9) 135 (41.5) 59 (42.8)
II-IIA 10 680 (22.4) 61 (18.8) 29 (21)
IIB 4257 (8.9) 18 (5.5) 19 (13.8)
Grade of first invasive cancer (14.6%)
Grade I 8115 (24.8) 49 (28) 13 (13.8)
Grade II 14 128 (43.2) 66 (37.7) 40 (42.6)
Grade III 10 461 (32.0) 60 (34.3) 41 (43.6)
Hormone receptor status of invasive first cancer (14.3%)
ER+ or PR+ 27 907 (85.1) 146 (83) 67 (76.1)
ER- and PR- 4893 (14.9) 30 (17) 21 (23.9)
Primary surgery (3.2%)
Mastectomy 15 964 (34.5) 57 (18.9) 32 (23.7)
Breast conserving with radiation 23 808 (51.5) 168 (55.6) 72 (53.3)
Breast conserving without radiation 6440 (13.9) 77 (25.5) 31 (23)
Adjuvant systemic therapy (6.3%)
None 21 882 (48.9) 195 (66.3) 64 (49.2)
Endocrine therapy only 11 800 (26.4) 45 (15.3) 21 (16.2)
Chemotherapy only 6353 (14.2) 34 (11.6) 31 (23.8)
Chemotherapy and endocrine 
therapy
4738 (10.6) 20 (6.8) 14 (10.8)
Imaging and surveillance characteristics
Mode of detection of first cancer (9.8%)
Screen-detected 27 657 (64.3) 180 (64.3) 57 (45.2)
Interval cancer in screening 7046 (16.4) 53 (18.9) 32 (25.4)
Clinical/diagnostic detected 6443 (15.0) 33 (11.8) 34 (27)
Other 1880 (4.4) 14 (5) 3 (2.4)
BI-RADS breast density (24.1%)
1 - Almost entirely fatty 2707 (7.5) 9 (3.7) 2 (1.9)
2 - Scattered fibroglandular tissue 17 013 (47.0) 109 (44.7) 38 (36.5)
3 - Heterogeneously dense 14 527 (40.1) 110 (45.1) 54 (51.9)
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significant variables in the model and used the most favorable 
category for statistically significant predictors. The least favora-
ble risk profile used referent categories for non-statistically 
significant predictors and the least favorable category for statis-
tically significant predictors.
Missingness in individual covariates ranged from 0% to 
24%. For the fully adjusted multivariable model, we used mul-
tiple imputation via chained equations to impute missing data 
(32,33). This method imputed each missing variable using a 
regression model conditional on all the other variables in the 
model; this was repeated for all variables with missing data. Five 
imputations were performed, and estimates were combined 
across imputations using standard methods for multiple impu-
tation (34).
All analyses were performed using R 2.15.0 (R Foundation for 
Statistical Computing, Vienna, Austria). All statistical tests were 
two-sided.
Results
The study population included 47 717 surveillance mammo-
grams in 15 114 women with a personal history of breast can-
cer. Median age at diagnosis was 60 years (interquartile range 
[IQR]  =  50–70  years). Most women were white, non-Hispanic 
(86%), postmenopausal (91%), and 24% reported a first degree 
relative with breast cancer. PBCs were predominantly hormone 
receptor–positive (85%). Most women received breast conserva-
tion and radiation therapy (52%) or mastectomy (35%), with a 
minority of women (14%) receiving breast conservation without 
radiation. Assessment of follow-up as measured by time from 
PBC diagnosis to last surveillance mammogram within the BCSC 
demonstrated a range of follow-up from less than one year to 
more than ten years, with median follow-up time between 
three and four years. Most women returned for multiple sur-
veillance rounds, with a median of three mammograms/woman 
(IQR  =  1–4), and 40 361 mammograms (85%) were obtained 
within nine to 14 months of a prior mammogram. Lasagna plots 
summarize the number of mammograms and length of follow-
up stratified by outcome of interest (Figure  1). A  minority of 
women had five mammograms within the five years of surveil-
lance (contiguous gray shaded area from left to right). Others 
received less frequent surveillance, had moved out of BCSC 
catchment areas, or entered our cohort less than five years prior 
to the end of study follow-up. Additional demographic, primary 
cancer, treatment, and imaging characteristics of the study 
population are presented in Table  1. Cancer detection rates 
and interval-invasive cancer rates per 1000 exams stratified by 
patient and primary breast cancer characteristics are shown in 
Supplementary Table 1 (available online).
Second Breast Cancers
Of the 463 second breast cancers diagnosed during the five-year 
follow-up period, 325 (70%) were surveillance-detected and 138 
(30%) were interval-invasive breast cancers. The cumulative 
incidence rate was 54.4 per 1000 women. There was no statisti-
cally significant difference in observed incidence rates by sur-
veillance round (P = .91), which ranged from 9.2 to 10.7 per 1000 
mammograms. The proportion of surveillance-detected and 
interval-invasive breast cancers also did not vary statistically 
significantly across surveillance rounds (P = .84).
Five-Year Risk of Interval-Invasive Second 
Breast Cancer
We estimated the five-year cumulative probability of an inter-
val-invasive second breast cancer after PBC treatment, initially 
fitting separate models for each covariate of interest, adjusted 
for BCSC registry and surveillance round only. Estimates from 
these minimally adjusted models ranged from 0.4% for women 
with almost entirely fatty breast density to 4.5% for women 
younger than 40 years at PBC diagnosis (Table 2).
The fully adjusted multivariable model, which included all 
covariates of interest simultaneously, identified grade of first 
cancer (P  =  .047), primary surgical treatment of first cancer (P 
< .001), PBC mode of detection (P = .004), and breast density on 
surveillance mammography (P = .024) as independent predictors 
of interval-invasive second breast cancers (Table 3). Specifically, 
women with intermediate-grade, compared with low-grade, 
primary invasive cancers had an elevated risk of interval-inva-
sive second breast cancer (OR  =  1.95, 95% confidence interval 
(CI) = 1.15 to 3.31). Women treated with breast conservation and 
radiation therapy had an elevated risk compared with women 
who underwent mastectomy (OR = 2.13, 95% CI = 1.35 to 3.36), 
and women treated with breast conservation without radiation 
therapy had further increased risk (OR = 3.27, 95% CI = 1.91 to 
5.62). Women whose PBCs presented as interval cancers after 
a negative screening mammogram (OR  =  2.01, 1.28 to 3.16) or 
women whose PBCs were detected clinically or on diagnostic 
Variable (proportion  
missing data for variable where applicable)




No. invasive interval 
second cancers (%)
Time since last mammogram (0.6%), mo
9–14 40 361 (85.1) 255 (79.7) 117 (85.4)
15–23 5470 (11.5) 45 (14.1) 13 (9.5)
24+ 1611 (3.4) 20 (6.2) 7 (5.1)
Time since first breast cancer diagnosis (0%), y
<1 4775 (10.0) 35 (10.8) 14 (10.1)
1–2 13 293 (27.9) 73 (22.5) 43 (31.2)
3–4 12 600 (26.4) 71 (21.8) 35 (25.4)
5–6 8801 (18.4) 76 (23.4) 25 (18.1)
7–9 6467 (13.6) 53 (16.3) 14 (10.1)
≥10 1781 (3.7) 17 (5.2) 7 (5.1)
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imaging were also more likely to have interval-invasive second 
breast cancers (OR = 2.12, 95% CI = 1.29 to 3.50) compared with 
women with screen-detected PBCs. While under surveillance, 
women with heterogeneously dense breasts on mammography, 
compared with scattered fibroglandular tissue, had higher odds 
ratios for interval-invasive second breast cancer (OR = 1.54, 1.01 
to 2.36). Of note, in the fully adjusted multivariable model, age 
at diagnosis, hormone receptor status, and first-degree family 
history were not statistically significant predictors of subse-
quent interval–invasive breast cancer. In sensitivity analyses, 
regardless of whether a one-year or two-year look-back period 
was used to define mode of detection, women whose PBCs were 
detected clinically or on diagnostic imaging were more likely to 
have interval-invasive second cancers compared with women 
with screen-detected PBCs.
Range of Cumulative Probability Across Varying Risk 
Profiles
To better understand the range of risk for an interval-invasive 
second breast cancer for women with varying combinations of 
risk factors, the fully adjusted model was used to estimate the 
cumulative probability of this outcome (Figure  2). A  woman 
with referent category characteristics for all predictors had a 
0.60% probability of an interval-invasive second breast can-
cer after five rounds of annual surveillance mammography. To 
create the most favorable risk profile, we adjusted the base-
case referent profile to reflect the most favorable categories 
of statistically significant predictors: screen-detected PBC, 
grade I, treated with mastectomy, and fatty breast tissue on 
surveillance mammography. A  woman with this profile had 
a projected cumulative probability of an interval-invasive 
second breast cancer of 0.07%. To create the least favorable 
risk profile, we adjusted the base-case referent profile to 
include the following characteristics: clinically detected PBC, 
grade II, treated with lumpectomy without radiation therapy, 
and extremely dense breast tissue on mammography. For a 
woman with this risk profile, the five-year cumulative prob-
ability was 6.11%.
Discussion
We identified predictors of increased five-year risk of interval-
invasive second breast cancer after PBC treatment. Our results 
indicate that factors known at the time of PBC diagnosis and 
treatment can predict subsequent second breast cancer out-
comes, and that the cumulative probability of an interval-inva-
sive second breast cancer during this period varies substantially 
for women with different combinations of these characteristics, 
Table  2. Cumulative probability of interval-invasive second breast 
cancer within five years of primary breast cancer diagnosis*
Characteristics
Cumulative 5-yr  
probability, % (95% CI)
Demographic characteristics
Race/ethnicity
White, non-Hispanic 1.4 (1.1 to 1.7)
Black, non-Hispanic 1.7 (0.3 to 4.0)
Hispanic 1.8 (0.8 to 3.4)
Asian, Pacific Islander 2.5 (0.0 to 5.8)
Other 1.0 (0.0 to 2.6)
Menopausal status
Post 1.3 (1.0 to 1.6)
Pre-, Peri- 2.6 (1.5 to 3.8)
First-degree family history of breast cancer
No 1.4 (1.1 to 1.8)
Yes 1.8 (1.2 to 2.5)
First cancer diagnosis and treatment characteristics
Age at first breast cancer, y
<40 4.5 (2.3 to 7.2)
40–49 1.8 (1.2 to 2.5)
50–59 1.2 (0.8 to 1.6)
60–69 1.3 (0.8 to 1.8)
70–79 1.1 (0.7 to 1.7)
80+ 1.5 (0.5 to 2.7)
Stage of first breast cancer
0 1.6 (1.1 to 2.3)
I 1.2 (0.9 to 1.6)
II-IIA 1.4 (0.9 to 1.9)
IIB 2.3 (1.3 to 3.4)
Grade of first invasive cancer
Grade I 0.8 (0.3 to 1.3)
Grade II 1.4 (1.0 to 2.0)
Grade III 1.9 (1.3 to 2.5)
Hormone receptor status of invasive first cancer
ER+ or PR+ 1.2 (0.9 to 1.6)
ER- and PR- 2.2 (1.2 to 3.1)
Primary surgery
Mastectomy 1.0 (0.6 to 1.3)
Breast conserving with radiation 1.5 (1.2 to 2.0)
Breast conserving without radiation 2.4 (1.6 to 3.2)
Adjuvant systemic therapy
None 1.4 (1.0 to 1.8)
Endocrine therapy only 0.9 (0.6 to 1.4)
Chemotherapy only 2.3 (1.5 to 3.3)
Chemotherapy and endocrine therapy 1.6 (0.8 to 2.5)
Imaging and surveillance characteristics
Mode of detection of first cancer
Screen-detected 1.0 (0.7 to 1.3)
Interval cancer in screening 2.2 (1.4 to 3.0)
Clinical/diagnostic detected 2.7 (1.8 to 3.7)
Other 0.8 (0.0 to 1.9)
BI-RADS breast density
1 - Almost entirely fatty 0.4 (0.0 to 0.9)
2 - Scattered fibroglandular tissue 1.1 (0.8 to 1.5)
3 - Heterogeneously dense 1.9 (1.3 to 2.5)
4 - Extremely dense 2.5 (1.1 to 4.3)
Time since first breast cancer diagnosis (0%), y
<1 1.9 (1.2 to 2.9)
1–2 1.7 (0.7 to 3.1)
3–4 1.4 (0.9 to 2.0)
5–6 1.4 (0.8 to 2.0)
Characteristics
Cumulative 5-yr  
probability, % (95% CI)
7–9 1.0 (0.4 to 1.9)
≥10 1.7 (0.4 to 4.6)
* Separate models were constructed for each covariate, adjusted only for Breast 
Cancer Surveillance Consortium registry and surveillance round. All statistical 
tests were two-sided. BI-RADS = American College of Radiology’s Breast Imag-
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from 0.07% in women with the most favorable risk profile to 
6.11% in women with the least favorable profile.
Because approximately 70% of in-breast recurrences 
occur within five years of treatment (35–37), our study 
focused on this surveillance period. Our results extend pre-
vious BCSC reports identifying predictors of second breast 
cancer diagnosis (20) and interval second cancer presenta-
tion within one year of negative surveillance mammography 
(18,19). Houssami, et  al. (19) identified age at PBC diagno-
sis younger than 40  years as the strongest predictor of an 
interval-invasive breast cancer, along with breast-conserving 
surgery without radiation, increased mammographic breast 
density, and first-degree family history of breast cancer. 
When considering a longer five-year surveillance horizon, 
multivariable modeling indicated that local treatment and 
breast density remained statistically significant predictors, 
but age at diagnosis and family history were not. PBC grade 
and mode of detection were additional independent predic-
tors in this analysis.
The differences in statistically significant predictors between 
two studies from the same mammography registries and study 
period can be attributed to the more stringent inclusion criteria 
used in this study. To estimate the five-year cumulative prob-
ability of interval-invasive second breast cancers, we needed to 
capture data regarding mammography use around the time of a 
woman’s PBC diagnosis and also to identify all post-treatment 
mammograms. This was not required in the prior study with 
a more limited one-year follow-up period after surveillance 
mammography (19). As a consequence, the overall sample size 
of women (15 114 vs 20 941)  and surveillance mammograms 
(47 717 vs 67 819) is relatively smaller but allowed longer-term 
follow-up. The proportion of missing data for the predictors of 
interest was also smaller in this study, in particular, PBC mode 
of detection was not included in the model of one-year surveil-
lance outcomes because of the proportion of missing data (19). 
In the current analysis, we were able to consider this predictor 
because greater than 90% of mode of detection data was cap-
tured. Another consequence of the smaller size of this current 
study is the inclusion of fewer women younger than 40 years 
of age at PBC diagnosis (1579 vs 2701) and fewer interval sec-
ond breast cancers (15 vs 29) in these women, and fewer women 
Table 3. Fully adjusted multivariable model of interval-invasive sec-
ond breast cancer within five years of primary breast cancer diag-
nosis*
Characteristics Fully Adjusted OR (95% CI) P†
Demographic characteristics
Race/ethnicity -- .807
White, non-Hispanic Referent --
Black, non-Hispanic 1.16 (0.39 to 3.45) .792
Hispanic 1.26 (0.61 to 2.59) .532
Asian, Pacific Islander 1.89 (0.53 to 6.72) .325
Other 0.73 (0.18 to 2.99) .663
Menopausal status -- --
Post Referent --
Pre-, Peri- 1.05 (0.48, 2.31) .909




Yes 1.42 (0.93 to 2.19) .108
First cancer diagnosis and treatment characteristics
Age at first breast cancer, y -- .399
<40 1.94 (0.69 to 5.42) .208
40–49 0.98 (0.47 to 2.02) .953
50–59 0.80 (0.48 to 1.33) .388
60–69 Referent --
70–79 0.91 (0.51 to 1.62) .745
80+ 1.16 (0.50 to 2.70) .736
Stage of first breast cancer -- .336
0 1.22 (0.75 to 1.99) .419
I Referent --
II-IIA 0.86 (0.52 to 1.40) .533
IIB 1.41 (0.78 to 2.55) .257
Grade of first invasive 
cancer
-- .047
Grade I Referent --
Grade II 1.95 (1.15 to 3.31) .014
Grade III 1.87 (0.96 to 3.64) .064
Hormone receptor status of 
invasive first cancer
-- --
ER+ or PR+ Referent --
ER- and PR- 1.11 (0.68 to 1.81) .679
Primary surgery -- <.001
Mastectomy -- --
Breast conserving with 
radiation
2.13 (1.35 to 3.36) .001
Breast conserving with-
out radiation
3.27 (1.91 to 5.62) <.001
Adjuvant systemic therapy -- .577
None Referent --
Endocrine therapy only* 0.71 (0.42 to 1.21) .21
Chemotherapy only 1.10 (0.61 to 1.99) .753
Chemotherapy and endo-
crine therapy
0.92 (0.47 to 1.78) .799
Imaging and surveillance characteristics




Interval cancer in screen-
ing
2.01 (1.28 to 3.16) .002
Clinical/diagnostic 
detected
2.12 (1.29 to 3.50) .003
Other 0.79 (0.25 to 2.52) .688
BI-RADS breast density -- .024
1 - Almost entirely fatty 0.25 (0.06 to 1.03) .054
2 - Scattered fibroglandu-
lar tissue
Referent --
3 - Heterogeneously dense 1.54 (1.01 to 2.36) .045
4 - Extremely dense 1.65 (0.78 to 3.48) .189
Characteristics Fully Adjusted OR (95% CI) P†




15–23 0.73 (0.40 to 1.34) .312
24+ 1.62 (0.73 to 3.60) .234




1–2 0.92 (0.48 to 1.76) .795
 3–4 0.68 (0.40 to 1.14) .143
5–6 0.61 (0.31 to 1.19) .148
7–9 0.44 (0.18 to 1.11) .081
≥10 0.75 (0.21 to 2.70) .659
* Model is adjusted for all covariates included in table plus Breast Cancer Sur-
veillance Consortium registry and number of prior surveillance mammograms. 
All statistical tests were two-sided. BI-RADS = American College of Radiology’s 
Breast Imaging Reporting and Data System; CI = confidence interval; ER = estro-
gen receptor; PR = progesterone receptor.
† For variables with more than two levels, P value in first row for that covariate 
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older than 80 years of age (2517 vs 3178), decreasing power to 
detect a statistically significant difference in interval-invasive 
cancer rates by age at diagnosis in the fully adjusted model.
Our results suggest that aggressive tumor biology in a wom-
an’s first breast cancer, which influences detection by screening 
mammography (21,38), may continue to mediate her subsequent 
surveillance outcomes. This is consistent with emerging evidence 
about the heterogeneity of breast cancer as a disease (39–41). 
Molecular profiling of breast cancers, which includes identifying 
genes associated with proliferation, is increasingly being used to 
guide treatment decisions (42–44). When molecular profiling is 
not performed it is possible to approximate breast cancer sub-
types using information from immunohistochemical analysis 
(42) on the presence or absence of hormone receptors, human 
epidermal growth factor receptor (HER2), and histologic grade.
While PBC hormone receptor status, grade, size, nodal status, 
and stage were included as predictors in our analysis, evaluation 
of chemotherapy and endocrine therapy was limited. As this 
information is incompletely captured by the SEER registry (45), 
our findings that 85% of breast cancers were hormone recep-
tor–positive and only 37% percent received endocrine therapy 
likely reflect both the limited ascertainment of treatment by the 
registry as well as potential underuse of appropriate therapy. We 
were also not able to evaluate HER2 or HER2-targeted therapy. 
This was an optional data element in BCSC tumor registries dur-
ing our study period (46), and the relatively high proportion of 
missing values precluded use of HER2 in the predictive model. 
Additional studies are needed to evaluate the contribution of 
HER2 status and breast cancer subtype to mammographic sur-
veillance outcomes.
Considerations for reducing the incidence of interval-
invasive second breast cancer events include interventions to 
improve primary treatment for initial breast cancer, such as 
increasing use of radiation therapy in women choosing breast 
conserving therapy and appropriate endocrine treatment or 
increasing post-treatment adherence with current guideline 
recommendations for annual surveillance mammography. Our 
findings also raise the possibility that the selective application 
of adjunctive testing to supplement surveillance mammogra-
phy, either with a more frequent surveillance interval (47) or 
with another modality such as breast MRI (48–51) or ultrasound 
(52), could reduce interval-invasive second breast cancers. 
However, population-based data on surveillance breast MRI or 
ultrasound is sparse, and evaluation of these modalities was not 
an aim for this analysis. Further studies are needed to examine 
the potential contribution of supplemental modalities or alter-
native regimens to improving surveillance outcomes.
In summary, our results suggest that factors related to PBC 
diagnosis and treatment—increased breast density, higher 
grade PBCs, interval PBC presentation, and breast conservation 
treatment without radiation therapy—contribute to variation in 
subsequent-interval second breast cancer risk. Consideration of 
these factors may help breast cancer survivors and their physi-
cians develop post-treatment breast imaging plans that are tai-
lored to patient-specific risks and preferences.
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Figure 2. Cumulative probability of interval-invasive second breast cancer for women with varying risk profiles. All profiles are for women who are non-Hispanic white, 
postmenopausal, age 60–69 years, stage I first cancers, ER+ or PR+ first cancers, and received no adjuvant therapy (non-statistically significant referent categories for 
predictors). Additional characteristics predictive of interval cancer risk are varied across profiles. Dotted line (most favorable risk profile): grade I first cancer, mastec-
tomy, American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS) 1 breast density, screen-detected first cancer. Solid line (referent category 
for all characteristics): grade I first cancer, lumpectomy with radiation, BI-RADS 2 breast density, screen-detected first cancer. Dashed line (least favorable risk profile): 
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